U.S. patent disclosures
Friday, December 27, 2013
Immunomedics Inc., of Morris Plains, N.J., received U.S. Patent No. 8,574,575 for RS7 antibodies. The patent relates to methods of use of the company’s TROP-2 antibody, and the allowed claim covers the use of IMMU-132, a SN-38 conjugate of TROP-2, for the treatment of cancer.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.